Statement of Work Technical Assistance to the Government of Kosovo to Improve Expenditure Tracking and Reporting/Build in-country Capacities/Enhance financial tracking and co-financing reportingBackground The main aim of the Global Fund’s
Sustainability, Transition and Efficiency Strategic Initiative (STE-SI) RSSH component is to support the implementation of the Global Fund Strategy 2017-2022. STE-SI also aims to accelerate the implementation of the Sustainability,
Transition, and Co-
Financing Policy, Global Fund’s efforts to strengthen domestic resource mobilization (DRM), and ongoing work to enhance Value for Money. The Health and Resource Tracking (HRT) component of the STE-SI supports the building of capacity of countries to routinely generate reliable data on health and disease spending to support monitoring of health investments,
costing of national plans, fiscal space analysis, and development of health financing strategies and sustainability plans. At the time of accessing grant funding under the 2017-2019 allocation, Kosovo needed to invest an additional US$xxxxM in 2017-2019 compared to the baseline, to meet the requirements of Global Fund’s Sustainability, Transition, and Co-
Financing (STC) policy (see table 1). Table Minimum Additional Co-Financing Requirements 2017-2019 Allocation
Program Allocation Co-Financing Incentive Minimum Additional Co-Financing HIV TB Total Specific co-financing commitments were negotiated as a transition country. The key focus of the Country Team was to obtain necessary commitments (co-financing and programmatic) to cover critical gaps mainly those
related to essential services, more specifically
• HIV treatment, care and support,
including treatment monitoring, OIs, and
OST/MMT program in the public sector in 5 regions. In addition HIV prevention in Health Services in Prison Systems blood safety
• TB TB treatment, TB case detection and diagnosis,
MOR-TB case detection,
MDR diagnosis and treatment , and maintaining infrastructure of TB facilities.
• Specific health product investments were towards o 100% of ARVs, first and MDR-TB drugs, methadone and CD and VL kits, as well as 100% solid and liquid
media for TB diagnostics